Stockholders approve merger with Crescent Biopharma; 1-for-100 reverse split

CRESCENT BIOPHARMA, INC.

Stockholders approved all 10 proposals including merger agreement, stock issuance, charter amendments, reverse split, and equity plans.
Board approved 1-for-100 reverse stock split; outstanding shares reduced from ~64.5M to ~0.6M.
Post-merger combined company to trade as Crescent Biopharma, Inc. (CBIO) on Nasdaq starting June 16, 2025.
Combined company expected to have ~14.8M shares outstanding (~25.3M fully diluted) post-merger.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.